



Clinical trial results:

A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome

Summary

EudraCT number	2010-024156-28
Trial protocol	DE
Global end of trial date	21 December 2017

Results information

Result version number	v1 (current)
This version publication date	16 September 2021
First version publication date	16 September 2021
Summary attachment (see zip file)	Publication (Krause et al. CAN in SchS JACI 2017.pdf) Publication (Krause et. al. CAN in SchS extension JACI 2020.pdf)

Trial information

Trial identification

Sponsor protocol code	CACZ885DDE03T
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Charité - University Hospital of Berlin
Sponsor organisation address	Charitéplatz 1, Berlin, Germany, 10117
Public contact	Clinical Trials Information, Charité - University Hospital of Berlin, +49 030450-518-342, karoline.krause@charite.de
Scientific contact	Clinical Trials Information, Charité - University Hospital of Berlin, +49 030450-518-342, karoline.krause@charite.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 December 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 December 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the effect of canakinumab on the clinical signs and symptoms of Schnitzler Syndrome (SchS)

Protection of trial subjects:

Canakinumab (Ilaris®, L04AC04, Novartis International AG, CH-4002 Basel, Switzerland) is a recombinant high-affinity monoclonal antibody that neutralizes IL-1 β , a key mediator of local and systemic inflammatory reactions. Canakinumab is indicated for adults and children over 4 years for treatment of cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS), MuckleWells syndrome (MWS) and neonatal onset multi-system inflammatory disease (NOMID/CINCA). In addition, it has been successfully tested for gout, systemic juvenile idiopathic arthritis (SJIA) and other autoinflammatory diseases. On the basis of the good response to treatment with anakinra it is supposed that canakinumab may be highly effective in SchS too. Safety assessment included adverse event reporting and routine clinical and laboratory assessments. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	20
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study started 05.07.2011 and ended on 21.12.2017. There were 15 patients who completed the whole study period of 4 years.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo (identical with study drug apart from active ingredient)

Arm title	Canakinumab
------------------	-------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Canakinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The first part was an initial 7-day double-blind, placebo-controlled study of a single subcutaneous dose of canakinumab 150 mg. The second part was a 16-week open-label follow-up to establish the optimal dose of canakinumab, 150 or 300 mg, and to assess adverse responses.

Number of subjects in period 1	Placebo	Canakinumab
Started	13	7
Completed	13	7

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Canakinumab
Reporting group description: -	

Reporting group values	Placebo	Canakinumab	Total
Number of subjects	13	7	20
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	13	7	20
From 65-84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	5	4	9
Male	8	3	11

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Canakinumab
Reporting group description: -	

Primary: The effect of canakinumab of canakinumab on the clinical signs and symptoms of SchS measured by physicians global assessment

End point title	The effect of canakinumab of canakinumab on the clinical signs and symptoms of SchS measured by physicians global assessment ^{[1][2]}
End point description: see report	
End point type	Primary
End point timeframe: 57 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: See report

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: See report

End point values	Canakinumab			
Subject group type	Reporting group			
Number of subjects analysed	7			
Units: Physician global assessment (0-20)				
median (inter-quartile range (Q1-Q3))	4 (0 to 5)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

During the whole trial

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	17 Patients
-----------------------	-------------

Reporting group description:

See manuscript

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: See manuscript

Serious adverse events	17 Patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 17 (41.18%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Leiomyoma			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Craniocerebral injury	Additional description: Due to assault; recovered		
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Multiple Myeloma			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Hernia inguinal	Additional description: Worsening of inguinal hernia; recovered		

subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumonia with consecutive paraplegia			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Sepsis	Additional description: Sepsis due to atypical mycobacteriosis; fatal outcome		
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	17 Patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 17 (0.00%)		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported